New York, New York 10021

  • Primary Peritoneal Cavity Cancer


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CT-2103 in treating patients who have recurrent ovarian epithelial or fallopian tube cancer or primary peritoneal cancer.

Study summary:

OBJECTIVES: - Determine the response rate and time to treatment failure in patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal carcinoma treated with CT-2103. - Determine the tolerability and safety of the previously established dose and schedule of CT-2103 in these patients. OUTLINE: This is a dose-escalation study. Patients receive CT-2103 IV over 10 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. If no more than 1 of the first 6 patients experience dose-limiting toxicity, then the remaining patients receive a higher dose of CT-2103. Patients are followed between 1-3 months and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma - Recurrent disease following prior initial therapy with platinum-based regimen - No more than 2 prior cytotoxic chemotherapy regimens for recurrent disease - No more than 1 prior non-platinum, non-taxane regimen - At least 1 site of radiographically measurable disease AND/OR - CA-125 levels at least 50% above upper limits of normal for a minimum of 2 samples PATIENT CHARACTERISTICS: Age - Not specified Performance status - Karnofsky 70-100% Life expectancy - Not specified Hematopoietic - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - Bilirubin less than 1.5 times upper limit of normal (ULN) - SGOT less than 1.5 times ULN - Alkaline phosphatase less than 1.5 times ULN Renal - Creatinine no greater than 1.5 mg/dL Other - No unresolved, pre-existing grade 2 or greater neurotoxicity from prior treatment with neurotoxic drugs - No active uncontrolled infection - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 4 weeks after study PRIOR CONCURRENT THERAPY: Biologic therapy - At least 4 weeks since prior immunotherapy and recovered Chemotherapy - See Disease Characteristics - At least 4 weeks since prior chemotherapy and recovered Endocrine therapy - At least 4 weeks since prior endocrine therapy and recovered Radiotherapy - At least 4 weeks since prior radiotherapy (except for palliative reasons) and recovered Surgery - Not specified Other - At least 4 weeks since other prior investigational drugs and recovered



Primary Contact:

Study Chair
Paul Sabbatini, MD
Memorial Sloan-Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10021
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.